Belkin Recalls Portable Wireless Chargers, Stand Special Edition

Australia Says Vaccine Choices Made on Best Medical Advice

The Australian government reaffirmed confidence in its “portfolio approach” to Covid-19 vaccines as the nation prepares to inoculate its population next month.

“That has been the best medical advice available to us. What we know with the AstraZeneca vaccine is that it’s safe, that it’s available, that it can be manufactured here, it can be transported at normal refrigeration levels,” Treasurer Josh Frydenberg said Thursday.

The clarification comes after some medical groups called for the government to pause the rollout of the AstraZeneca Plc vaccine because of concern that it may not be effective enough to generate herd immunity. Subject to approvals, front line workers and aged-care residents in Australia will start to get the vaccine next month, with general practitioners and pharmacies using the AstraZeneca vaccine and hospitals the Pfizer Inc. dose, due to the latter’s storage requirements.

“The AstraZeneca vaccine saves lives and it is important, as the epidemiologists and the microbiologists and other health experts tell us, to get that vaccine out to Australians and to ensure that the Covid-19 infections do not increase across the community,” Frydenberg told Sky News.

READ MORE:Australia to Rely on GP Doctors, Drug Stores for Vaccine Rollout

Lumentum To Acquire Coherent In $5.7 Bln Cash & Stock Deal – Quick Facts

Lumentum Holdings Inc. and Coherent, Inc. have entered into a definitive agreement under which Lumentum will acquire Coherent in a cash and stock deal valued at $5.7 billion. Coherent stockholders will receive $100.00 per share in cash and 1.1851 shares of Lumentum common stock for each Coherent share. The transaction is expected to close in the second half of calendar year 2021.

The combined company is anticipated to generate more than $150 million in annual run-rate synergies within 24 months of the closing of the deal. The transaction is projected to be accretive to the combined company’s non-GAAP earnings per share during the first full year after the close of the transaction.

ICM Partners Signs Jim Sturgess

EXCLUSIVE: Jim Sturgess has signed with ICM Partners for representation in all areas.

The London-based actor, known for constantly embodying a wide range of characters, is currently shooting the second season of the Apple series Home Before Dark, a small-town mystery in which he stars opposite Brooklynn Prince.

HIs breakthrough role in Julie Taymor’s musical drama Across the Universe launched his career and he went on to star in several critically acclaimed films including starring opposite Natalie Portman and Scarlett Johansson in period drama The Other Boleyn Girl, and playing the lead role opposite Kevin Spacey as an MIT math whiz who takes down a Vegas casino in 21 .

He next starred opposite Colin Farrell and Saoirse Ronan as a Polish prisoner of war in Peter Weir’s film The Way Back. He also starred opposite Tom Hanks and Halle Berry in the epic sci-fi fiction film Cloud Atlas, directed by The Wachowskis and Tom Tykwer.

Other credits include The Best Offer directed by Giuseppe Tornatore opposite Geoffrey Rush, Electric Slide, Geostorm opposite Gerard Butler.

He continues to be represented by Megan Willis of Garrick in the U.K., Hanson Jacobson Teller Hoberman Newman Warren Richman Rush Kaller & Gellman and Independent Public Relations.

Read More About:

IPO Lockup Expiration Alert: Nkarta Inc. (NKTX)

The lockup period of Nkarta Inc. (NKTX) expires tomorrow, i.e. on Jan 6.

South San Francisco, California-based Nkarta Inc. is a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

There are two product candidates in the pipeline – NKX101 and NKX019.

NKX101 is under a phase I trial for the treatment of relapsed/refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndromes (MDS). The first patient in this trial was treated as recently as November 2020.

As for NKX019, an investigational NK cell therapy engineered to target tumors expressing CD19 antigen for the treatment of B-cell malignancies, the company expects to file an Investigational New Drug (IND) Application this quarter.

Nkarta made its debut on The Nasdaq Global Select Market on July 10, 2020, offering its shares at a price of $18 each and the 180 day lockup period expires tomorrow.

NKTX opened the first day of trading on July 10 at $54.45 and closed at $47.90 that day. The stock has thus far hit a low of $22.46 and a high of $79.16.

NKTX closed Tuesday’s trading at $56.48, down 5.25%

Belkin Recalls Portable Wireless Chargers, Stand Special Edition

Consumer electronic products maker Belkin has announced a voluntary recall of Portable Wireless Charger + Stand Special Edition that was sold in Apple retail stores and online on Apple and Belkin’s sites because of fire and shock safety hazards.

Belkin has recalled about 2,2800 Portable Wireless Charger + Stand Special Edition due to a manufacturing defect in the power supply unit that can cause the charger to malfunction and overheat, posing fire and shock hazards.

No incidents or injuries have been connected to the charger, according to the Consumer Product Safety Commission. The recall products were sold between July 2020 and October 2020 for about $80.

he wireless charging stand has a 10,000mAh power capacity and can charge at 10W speed for phones that support it. Belkin has asked customers to immediately stop using the recalled portable wireless chargers. The company will also give refunds to anyone who owns the recalled charger.